Monoclonal antibody therapeutics and risk for infection

Pediatr Infect Dis J. 2007 Nov;26(11):1049-52. doi: 10.1097/INF.0b013e31815a044f.
No abstract available

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Animals
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / adverse effects
  • Antibodies, Neoplasm / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Immunosuppression Therapy
  • Infections / etiology*
  • Lymphocytes / immunology
  • Lymphocytes / physiology
  • Mice
  • Natalizumab
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Natalizumab
  • Tumor Necrosis Factor-alpha
  • Alemtuzumab